Nitrite Reductase Inhibition for Dormant Tuberculosis Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis treatment methods are ineffective in detecting and addressing dormant Mycobacterium tuberculosis bacilli, leading to drug resistance and prolonged treatment periods, as they fail to accurately assess the conversion of active to dormant bacilli and do not effectively kill dormant bacilli present in patients.
Innovation Solution
Targeting nitrite reductase as a potential drug target within the nitrate metabolic pathway, specifically using inhibitors like p-hydroxy mercuric benzoate to inhibit nitrite reductase, which is essential for the survival of Mycobacterium tuberculosis under hypoxic conditions, and employing a method to detect nitrite in body fluids as a diagnostic tool for identifying various stages of tuberculosis infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple antibiotics are administered over a long period to treat TB, then treatment coverage is improved, but drug resistance develops and treatment complexity increases
Solution Approach 1:
The patent applies preliminary action by detecting nitrite levels in clinical samples to identify dormant bacilli before they cause treatment failure or drug resistance. By assessing the nitrate metabolic pathway activity in advance, clinicians can adjust treatment regimens proactively to prevent the development of drug-resistant strains, rather than waiting for resistance to manifest during prolonged multi-drug therapy.
2Measurement precision
If culture methods are used to diagnose TB, then diagnostic accuracy is improved, but detection time is prolonged
Solution Approach 1:
The patent replaces the mechanical culture system with a biochemical detection system based on the nitrate metabolic pathway. Instead of waiting for bacterial growth in culture media, the method detects nitrite levels produced by dormant bacilli through chemical reactions (Griess reaction), providing rapid results within hours rather than weeks while maintaining diagnostic accuracy for both active and dormant stages.
3Productivity
If nitrite detection method is implemented, then diagnostic speed is improved, but detection complexity increases
Solution Approach 1:
The patent employs disposable colorimetric reagents and simple visual or spectrophotometric detection systems rather than complex automated analytical instruments. The Griess reagent system is inexpensive, single-use, and requires minimal training, making the rapid nitrite detection method accessible in resource-limited settings without requiring sophisticated laboratory infrastructure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively kills dormant bacilli and provides a rapid, cost-effective diagnostic method for tuberculosis, correlating nitrite levels with disease severity, enabling better monitoring of treatment efficacy and identifying drug-resistant strains.
Implementation Method 1
nitrite reductase (MRA—0261)... converts nitrite to ammonia... essential for the survival of Mycobacterium tuberculosis under hypoxic conditions
Implementation Method 2
using inhibitors like p-hydroxy mercuric benzoate to inhibit nitrite reductase... effectively kills dormant bacilli
Implementation Method 3
employing a method to detect nitrite in body fluids as a diagnostic tool... detecting color intensity of the solution... correlating nitrite levels with disease severity
Data Source
AI summary
The present invention discloses functional nitrite reductase as a potential drug target for anti-tubercular drug development. The present invention also relates to the development of an easy method for identification of nitrite in clinical samples as well as its correlation with the severity of the disease. Presence of active as well as dormant/latent stages of Mycobacterium tuberculosis (MTB) could be identified from nitrite in clinical samples like sputum of potential TB patients.


